Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”
Crossref DOI link: https://doi.org/10.1007/s00259-017-3773-6
Published Online: 2017-07-13
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hindié, Elif
Mesguich, Charles
Bouabdallah, Krimo
Milpied, Noël
License valid from 2017-07-13